meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
Age > 65y
Asian type
ECOG 0
ECOG 1
Gender, female
Gender, male
PD-L1 < 1%
PD-L1 < 10%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 10%
PD-L1 > 5%
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE leading to death (grade 5)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral sensory neuropathy TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
DCR
mEC - 2nd line (L2)
metastatic/advanced - esophageal cancer (mEC)
mEC - 2nd line (L2)
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC)
1
0.36
[0.23; 0.56], 1 RCT, I2=0%
statistically significant harm
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open